Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
26 Outubro 2023 - 9:30AM
Inozyme Pharma, Inc. (Nasdaq: INZY)
(“Inozyme” or the “Company”), a clinical-stage rare disease
biopharmaceutical company developing novel therapeutics for the
treatment of pathologic mineralization and intimal proliferation,
today announced an oral presentation at the American Society of
Nephrology (ASN) Kidney Week 2023, which is being held November
2-5, 2023 in Philadelphia, PA.
Details of the presentation are as follows:
Title: Role of Plasma Inorganic Pyrophosphate
in Calciphylaxis: A Prospective StudyFormat: Oral
Abstract Session – Research Advances in Bone and Mineral
MetabolismDate: Thursday, November 2,
2023Session Time: 5:42-5:51 p.m.
ETPresenting Author: Api Chewcharat, M.D., M.P.H.
(Clinical Fellow, Nephrology, Massachusetts General Hospital)
Senior Author: Sagar Nigwekar, MD, MMSc
(Co-Director, Kidney Research Center, Massachusetts General
Hospital)
Calciphylaxis is a rare disorder with a high mortality rate that
mostly affects patients with end stage kidney disease (ESKD). The
disease is associated with low levels of pyrophosphate (PPi) and is
characterized by pathologic mineralization and intimal
proliferation (the overgrowth of smooth muscle cells inside blood
vessels) of the vasculature in the skin and fatty tissue leading to
blood clots, painful skin ulcers, serious infections, and death.
Patients with calciphylaxis have a reported one-year survival rate
of approximately 50%. The estimated incidence of calciphylaxis is
at least 1,800 new patients per year in the United States and there
are no approved therapies.
Inozyme previously presented data at the European Calcified
Tissue Society Congress (ECTS) which showed that morbidity and
mortality in patients with calciphylaxis were associated with low
levels of PPi. The Company has received allowance of its
investigational new drug (IND) application from the U.S. Food and
Drug Administration (FDA) to evaluate INZ-701 in a clinical trial
in patients with ESKD and calciphylaxis.
About INZ-701
INZ-701, a recombinant Fc fusion protein, is an ENPP1 enzyme
replacement therapy in development for the treatment of rare
disorders of the vasculature, soft tissue, and skeleton. In
preclinical studies, the experimental therapy has shown potential
to prevent pathologic mineralization and intimal proliferation,
which can drive morbidity and mortality in devastating genetic
disorders such as ENPP1 Deficiency and ABCC6 Deficiency. INZ-701 is
currently in clinical trials for the treatment of ENPP1 Deficiency
and ABCC6 Deficiency.
About Inozyme Pharma
Inozyme Pharma, Inc. is a clinical-stage rare disease
biopharmaceutical company developing novel therapeutics for the
treatment of diseases impacting the vasculature, soft tissue, and
skeleton. Inozyme is developing INZ-701, an enzyme replacement
therapy, to address pathologic mineralization and intimal
proliferation which can drive morbidity and mortality in these
severe diseases. INZ-701 is currently in clinical trials for the
treatment of ENPP1 Deficiency and ABCC6 Deficiency.
For more information, please
visit www.inozyme.com or follow Inozyme
on LinkedIn, X (formerly
Twitter), and Facebook.
Cautionary Note Regarding Forward-Looking
Statements
Statements in this press release about future expectations,
plans, and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements" within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to the availability of
data from clinical trials, and the potential benefits of INZ-701.
The words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "will," "would," and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in,
or implied by, such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks associated
with the Company's ability to conduct its ongoing clinical trials
of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency; enroll
patients in ongoing and planned trials; obtain and maintain
necessary approvals from the FDA and other regulatory authorities;
continue to advance its product candidates in preclinical studies
and clinical trials; replicate in later clinical trials positive
results found in preclinical studies and early-stage clinical
trials of its product candidates; advance the development of its
product candidates under the timelines it anticipates in planned
and future clinical trials; obtain, maintain, and protect
intellectual property rights related to its product candidates;
manage expenses; comply with covenants under its outstanding loan
agreement; and raise the substantial additional capital needed to
achieve its business objectives. For a discussion of other risks
and uncertainties, and other important factors, any of which could
cause the Company's actual results to differ from those contained
in the forward-looking statements, see the "Risk Factors" section
in the Company's most recent Annual Report on Form 10-K filed with
the Securities and Exchange Commission, as well as discussions of
potential risks, uncertainties, and other important factors, in the
Company's most recent filings with the Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent the Company's views as of the date
hereof and should not be relied upon as representing the Company's
views as of any date subsequent to the date hereof. The Company
anticipates that subsequent events and developments will cause the
Company's views to change. However, while the Company may elect to
update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do
so.
Contacts
Investors:Inozyme PharmaStefan Riley, Director of IR and
Corporate Communications(857)
330-8871stefan.riley@inozyme.com
Media:SmithSolveMatt Pera(973)
886-9150matt.pera@smithsolve.com
Inozyme Pharma (NASDAQ:INZY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Inozyme Pharma (NASDAQ:INZY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024